PETMED EXPRESS Reports 11.5% Increase in Total Revenue for FY2024 Q1

☀️Earnings Overview

On July 31 2023, PETMED EXPRESS ($NASDAQ:PETS) revealed their FY2024 Q1 earnings results with total revenue increasing to USD 78.2 million, signifying a 11.5% year-over-year rise. Unfortunately, net income for the quarter was reported to be USD -0.89 million – a drop from the 2.78 million reported in FY2023 Q1.

Analysis

GoodWhale has conducted an in-depth analysis of PETMED EXPRESS‘s fundamentals and their findings are available for review. According to their Risk Rating, PETMED EXPRESS is a medium risk investment in terms of financial and business aspects. While the majority of the company’s financials appear to be solid, GoodWhale has detected 1 risk warning in the balance sheet that should be addressed before investing. To access more details, be sure to register on goodwhale.com. There you can find out more information on the company’s financials and any potential risks associated with the investment. More…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Petmed Express. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Petmed Express. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Petmed Express. More…

Key Ratios Snapshot

Some of the financial key ratios for Petmed Express are shown below. More…

Peers

PetMed Express Inc is one of the largest online pet pharmacies in the United States. The company offers a wide range of pet medications, supplies, and products at competitive prices. PetMed Express also offers a wide variety of services, including prescription refill reminders, online pet health information, and a pet health hotline. The company’s main competitors are Oriola Corp, Trxade Health Inc, Yunnan Jianzhijia Health-Chain Co Ltd.

– Oriola Corp ($LTS:0NER)

Oriola Corporation is a Finnish company that provides branded pharmaceuticals and services to the pharmaceutical industry and retail pharmacies. The company has a market capitalization of €330.77 million and a return on equity of 7.73%. Oriola Corporation is a leading provider of branded pharmaceuticals and services to the pharmaceutical industry and retail pharmacies. The company offers a wide range of products and services, including branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) products, medical devices, and services.

– Trxade Health Inc ($NASDAQ:MEDS)

Trxade Health Inc is a healthcare company that focuses on providing services and products to the healthcare industry. The company has a market cap of 8.16M as of 2022 and a Return on Equity of -110.47%. Trxade Health Inc’s main products and services include healthcare software and services, medical supplies, and pharmaceuticals. The company operates in the United States and Canada.

– Yunnan Jianzhijia Health-Chain Co Ltd ($SHSE:605266)

Yunnan Jianzhijia Health-Chain Co Ltd is a Chinese company that focuses on the development and application of health-related big data technology. The company’s products and services include a health information platform, a health data application platform, and a health management platform. As of 2022, Yunnan Jianzhijia Health-Chain Co Ltd has a market cap of 5.46B and a Return on Equity of 11.7%.

Summary

PETMED EXPRESS reported its FY2024 Q1 earnings results on July 31 2023. Total revenue increased 11.5% year-over-year to USD 78.2 million, but net income decreased to USD -0.89 million, a decline from 2.78 million in the same period last year. Despite this, the stock price rose on the day of the announcement.

This could indicate that investors are confident in the company’s ability to improve its financial performance in future quarters. Analysts should continue to watch PETMED EXPRESS to ascertain whether its growth can continue and if new strategies will be successful in increasing profitability over time.